（於開曼群島註冊成立的有限責任公司） （股份代號：1515） 董事名單及其角色和職能 華潤醫療控股有限公司的董事會（「董事會」）成員載列如下： 執行董事 于海， 董事長兼總裁 楊敏， 首席財務官 非執行董事 葛路 獨立非執行董事 胡定旭 傅廷美 周鵬 羅詠詩 董事會設立三個委員會，即審核委員會、提名委員會及薪酬委員會。各董事會成 員在該等委員會所擔任的職位載列如下。 | | 委員會 | 審核 | 提名 | 薪酬 | | --- | --- | --- | --- | --- | | 董事 | | 委員會 | 委員會 | 委員會 | | 于海 | | | C | | | 楊敏 | | | | | | 葛路 | | | | M | | 胡定旭 | | | M | C | | 傅廷美 | | C | | M | | 周鵬 | | M | | | | 羅詠詩 | | M | M | | 附註： C 有關董事委員會之主席 M 有關董事委員會之成員 中國，2025年8月26日 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 執行董事辭任 華 潤 醫 療 控 股 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）之 董 事（「 董 事」）會（「董事會」）謹此宣佈，單寶杰先生（「單先生」）因其他工作安排辭任執行董 事 職務 ，自 2025 年 8 月26 日起 生效 。 於單 先生 辭任 執 行董 事後 並 於同 日起 ， 彼亦 不再擔任本公司副總裁。單先生已確認，彼與董事會概無意見分歧，亦無任何有 關彼辭任的事宜須提呈本公司股東及香港聯合交易所有限公司垂注。 董事會藉此衷心感謝單先生任內作為執行董事對本集團作出的寶貴貢獻。 承董事會命 華潤醫療控股有限公司 董事長 于海 中國，2025年8月26日 於 本 公 告 日 期 及 作 出 上 述 變 更 後 ， ...

Core Insights - China Resources Medical is actively responding to new compliance requirements in the healthcare service industry by optimizing its business structure and steadily exiting the IOT business [1][2] - The company operates 105 medical institutions across 10 provinces and cities in China, with a reported total revenue of 9.855 billion yuan and a net profit of 672 million yuan for the year 2024 [1] - The distinction between "consolidated profit" and "distributable profit" is emphasized in the financial disclosures, particularly regarding the income from non-profit hospitals [1] Group 1 - The company has terminated IOT agreements with several hospitals, including Beijing Coal Group General Hospital and Shunyi District Airport Hospital, ensuring a smooth transition [1] - The financial report highlights the importance of accurately disclosing profit components, particularly the need to differentiate between the surplus from non-profit hospitals and distributable profits [1] - Future paths for state-owned enterprises in healthcare may include transitioning non-profit institutions to for-profit status and clarifying profit distribution in financial disclosures [1] Group 2 - As a benchmark for state-owned enterprises in healthcare, China Resources Medical balances its public health mission with shareholder return responsibilities, which raises development expectations [2] - The company integrates ESG principles into its development strategy, focusing on grassroots healthcare construction and public health responsibilities [2] - The exit from the IOT business is a significant step in compliance construction, with plans to optimize revenue structure and control operational costs to enhance efficiency [2]

Core Viewpoint - China Resources Medical's net profit is expected to be halved after excluding one-time gains, facing dual pressures from medical insurance cost control and strategic transformation, exemplified by the shutdown of Huaiyin Hospital, acquired for 883 million yuan, after three years of operation [1][2][3]. Group 1: Financial Performance - The announcement reveals two main reasons for the decline in performance: ongoing pressure from medical insurance cost control, which has compressed average costs per patient and significantly narrowed operating profit margins [2][4]. - The strategic transformation pain is evident as the company gradually divests from the previously profitable IOT (Investment-Operation-Transfer) business model, leading to a sharp reduction in related revenues [2][4]. - Without the one-time gain of approximately 210 million yuan from the Yanhua IOT agreement expected in the first half of 2025, the core profitability decline would be even more alarming, projected to drop by 55% to 60%, nearly halving [2][4]. Group 2: Strategic Adjustments - A significant strategic contraction has drawn market attention, as the company plans to shut down Jiangsu Huaiyin Hospital, acquired for 883 million yuan in 2021, due to ongoing operational deterioration and increasing losses [3][4]. - Financial data indicates that this acquisition has become a "hot potato," with revenues dropping over 50% in 2022 and over 60% in 2023, leading to cumulative losses nearing 200 million yuan over three years [4]. - In response to these challenges, the company stated it will focus on improving revenue structure, promoting refined management, strictly controlling operating costs, and enhancing operational efficiency in the second half of the year [4]. Group 3: Industry Context - The performance warning and project shutdown reflect the broader challenges faced by medical groups under the backdrop of public hospital reform and deepening medical insurance cost control, highlighting the need for a reconstruction of profit models [4]. - The company, as the only listed platform in China Resources Group's health sector, operates 105 medical institutions with over 20,000 beds across 10 provinces, yet its revenue for 2024 has already declined by 2.5% year-on-year, with the impact of medical insurance cost control explicitly mentioned in the annual report [4].

格隆汇8月14日丨华润医疗(01515.HK)公布，谨定于2025年8月26日(星期二)举行董事会会议，以考虑及 通过公司及其附属公司截至2025年6月30日止六个月的综合中期业绩及其发布、考虑派发中期股息(如 有)，以及处理其他事项。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 華潤醫療控股有限公司 董事長 于海 中國，2025年8月14日 於本公告日期，董事會成員包括執行董事于海先生、單寶杰先生及楊敏女士；非 執行董事葛路女士；獨立非執行董事胡定旭先生、傅廷美先生、周鵬先生及羅詠 詩女士。 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 董事會會議日期 華潤醫療控股有限公司（「本公司」）董事（「董事」）會（「董事會」）茲通告謹定於2025 年 8 月 26 日（ 星 期 二 ）舉 行 董 事 會 會 議 ， 以 考 慮 及 通 過 本 公 司 及 其 附 屬 公 司 截 至 2025 年6 月 30 日 止六個 月的綜 合中期 業績及 其發佈 、考慮 派發中 期股 息（ 如有 ）， 以及處理其他事項。 承董事會命 ...

智通财经APP获悉，根据联交所资料显示，8月5日，富达国际增持华润医疗(01515)291.15万股，每股作 价3.6936港元，总金额约为1075.39万港元。增持后最新持股数目约为1.05亿股，最新持股比例为8.1%。 本交易涉及其他关联方：Pandanus Associates Inc.、Pandanus Partners L.P.。 ...

根据2025年8月6日披露数据，华润医疗（01515）、长飞光纤光缆（06869）、英诺赛科（02577）港股 通持股占比增加值最大，分别增加3.12%、1.71%、1.12%；恆生中国企业（02828）、盈富基金 （02800）、龙蟠科技（02465）港股通持股占比减少值最大，分别减少-18.37%、-8.53%、-3.07%。 2、港股通最新日占比减持榜（前20名） | 公司名称 | 占比值变动 | 最新持股比例 | | --- | --- | --- | | 恆生中国企业(02828) | -18.37% | 0.65% | | 盈富基金(02800) | -8.53% | 0.65% | | 龙蟠科技(02465) | -3.07% | 48.38% | | 南方恆生科技(03033) | -2.60% | 59.94% | | 山东墨龙(00568) | -2.14% | 56.01% | | 重庆钢铁股份(01053) | -2.05% | 33.91% | | 优必选(09880) | -1.08% | 25.40% | | --- | --- | --- | | 宜搜科技(02550) | - ...

Core Viewpoint - The healthcare sector in Hong Kong is experiencing significant turbulence, primarily due to the impact of medical insurance cost control policies and the transition to a new payment system, which is leading to declining profits for companies like China Resources Medical [1][3][11]. Company Summary - China Resources Medical's stock price plummeted by 15.58% on August 4, reaching a closing price of HKD 3.73, with a market capitalization of HKD 48.5 billion [1]. - The company issued a profit warning, expecting a 20%-25% year-on-year decline in profits for the first half of the year, with a projected 55%-60% drop in net profit attributable to shareholders after excluding one-time gains of HKD 210 million [1][3]. - In 2024, the company reported a revenue of HKD 9.855 billion, a decrease of 2.5% year-on-year, primarily due to the impact of medical insurance cost control, with outpatient and inpatient average revenue per case declining by 2.4% and 4.3%, respectively [3][11]. - The company is gradually exiting the Investment-Operation-Transfer (IOT) business model, which has also contributed to the decline in profits, indicating a structural adjustment in its business operations [4][5]. Industry Summary - The challenges faced by China Resources Medical are reflective of broader issues within the healthcare industry, as many private hospitals are experiencing pressure on their performance due to similar factors [6][12]. - International Medical, another major player, has forecasted a net loss of HKD 160 million to HKD 170 million for the first half of 2025, attributing this to market fluctuations and the impact of the DRG payment reform [6][7]. - The DRG payment reform, set to deepen in 2025, fundamentally alters the revenue model for hospitals, shifting from fee-for-service to fixed payments based on disease categories, which limits revenue growth opportunities [3][11]. - The industry is witnessing a trend of increasing differentiation, with companies like International Medical focusing on high-value medical services and diversifying into non-insurance revenue streams to mitigate the impact of declining average fees [8][12]. - The ongoing reforms are expected to force hospitals to enhance cost control and management efficiency, leading to a healthier industry structure in the long term, despite short-term performance pressures [11][12].

本文源自：金融界 预期利润下降主要由于医保次均用下降致成员医疗机构经管利润下降。同时本公司逐渐退出IOT(即投 资-运营-移交模式)业务，其对应的利润贡献下降。2025年下半年本公司将继续积改善收入结构，推动管 理精细化，控制运管成本，提高经营效益。 | 香港交易及结算所有限公司及香港哪合交易所有限公司對本公告的内容廣不良 | 本公司仍在落實本則國於報告開之起合財務嚴表。本公告所載資料乃慰獲本公司 | | --- | --- | | 青、封其律破性设完整性冰不管表任何登明,崇明建表示题不到国本公告全高或 | Ⅰ 面已有资料 · 以及男本集膳波腹含刷风未提酱肝的综合管理服目之初步評估面 | | 任何部分歧容画產生或因綺麗華內容面引發的任何損失承擔任何责任。 | 作出 · 商〔等資料商未服本公司溶胚委員會及本公司之程數間簽回 · | | | 服東及滑在投資者於買賣本公司股份時期購獲得利率從建議參考本公司於2025年 | | > 華潤醫療控股有限公司 | 8月底開啟報告開樂刊發的中開風蘭公告所載之詳情, | | China Resources Medical Holdings Company Limited | 产 ...